XORTX Therapeutics logo
XORTX Therapeutics
XRTX | NASDAQ
Chart Builder DCF Calculator
$1.04
-$0.06 (-5.45%)
At close: Nov 16, 2026, 4:00 PM ET
$1.01
-$0.03 (-2.88%)
After-hours: Nov 16, 2026, 7:57 PM ET

XORTX Therapeutics Company Profile

Company profile explained

Company Profile

XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.

Key Executives

Name Position
Allen Warren Davidoff Founder, Co-CEO, President & Director
Mika Grasso Co-CEO & Director
Michael Scott Bumby Chief Financial Officer
Charlotte May Corporate Secretary
David MacDonald Consultant of Clinical Operations
David Sans Director of Corporate Development
Nick Rigopulos Director of Communications
Stacy Evans Chief Business Officer
Stephen Haworth MRCP Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 08, 2026 6-K Filing
Sep 18, 2026 6-K Filing
Sep 10, 2026 6-K Filing
Sep 09, 2026 6-K Filing
Sep 04, 2026 6-K Filing
Aug 28, 2026 6-K Filing
Aug 17, 2026 6-K Filing
Aug 04, 2026 6-K Filing
Jul 29, 2026 6-K Filing
Jun 15, 2026 6-K Filing
View All SEC Filings ➞
XORTX Therapeutics
XORTX Therapeutics logo
Country Canada
IPO Date Sep 23, 2021
Industry Biotechnology
Sector Healthcare
Employees 2
CEO Allen Warren Davidoff

Contact Details

3710 - 33rd Street NW Calgary, AB T2L 2M1 Canada

Stock Details

Ticker Symbol XRTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001729214
CUSIP Number 98420Q405
ISIN Number CA98420Q4051
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.